NKT-Like (CD3+CD56+) Cells in Chronic Myeloid Leukemia Patients Treated With Tyrosine Kinase Inhibitors

Therapy with Tyrosine Kinase Inhibitors (TKI) aiming stable deep molecular response is the gold standard to treat Chronic Myeloid Leukemia (CML). NKT-like cells (CD3(+)CD56(+)) combine characteristics of T and NK cells. The physiopathological role of these cells remains unknown although the literatu...

Descripción completa

Detalles Bibliográficos
Autores principales: Almeida, Jani-Sofia, Couceiro, Patrícia, López-Sejas, Nelson, Alves, Vera, Růžičková, Lenka, Tarazona, Raquel, Solana, Rafael, Freitas-Tavares, Paulo, Santos-Rosa, Manuel, Rodrigues-Santos, Paulo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6817724/
https://www.ncbi.nlm.nih.gov/pubmed/31695700
http://dx.doi.org/10.3389/fimmu.2019.02493

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6817724/
https://www.ncbi.nlm.nih.gov/pubmed/31695700
http://dx.doi.org/10.3389/fimmu.2019.02493

Ejemplares similares